PRESS RELEASE
16 May 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, HONG KONG, JAPAN, CANADA, SINGAPORE, OR SOUTH AFRICA OR IN ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF SANIONA.
Saniona AB (publ) (" Saniona " or the " Company ") (Nasdaq First North ticker: SANION) intends to undertake a private placement of up to SEK 25-35 million (the "Private Placement"). The possible Private Placement is directed to Swedish and international institutional investors and is, inter alia, subject to the board of directors of Saniona (the "Board") resolving to issue new shares following the completion of the Private Placement accelerated book building process that will be carried out by Pareto Securities AB (" Pareto Securities ") and Translution Capital A/S (" Translution Capital ").
The subscription price for the shares and the total number of shares to be issued in the Private Placement will be determined in a book building process. The book building process will begin no earlier than 17.31 (CET) on May 16, 2017, and end before the commencement of trading on Nasdaq First North on May 17, 2017. The minimum order will be set at the number of shares corresponding to EUR 100,000. The book building process for the Private Placement may close earlier or later at the discretion of the Company and the Company can choose to cancel the book building in its sole discretion for any reasons and at any time.
The rationale for carrying out the Private Placement is to provide the Company with an additional cash buffer in order to have increased flexibility to execute the Company's business plan in preparation for a list change to Nasdaq Stockholm expected in 2017.
The reason for deviating from the shareholders' preferential rights in the Private Placement is to broaden the shareholder base and that a directed share issue means lower costs and a faster process which altogether and with sufficient strength indicate that it is in the Company's and the shareholders' interest that the issue is made with deviation from the shareholders' preferential rights.
Pareto Securities has been appointed Sole Manager and Joint Bookrunner and Translution Capital has been appointed as Joint Bookrunner in connection with the Private Placement.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
The information in this interim report is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 17:31 CET on 16 May 2017.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 5,000 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com .
IMPORTANT INFORMATION
The release, publication or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipient of this press release is responsible for using the information in this press release in accordance with applicable law in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Australia, New Zealand, Hong Kong, Japan, Canada, Singapore or South Africa or in any other jurisdiction where the release, publication or distribution of the information would not comply with applicable laws and regulations.
This press release is not a prospectus for the purposes of Directive 2003/71/EC as amended through Directive 2010/73/EU. The Company has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus or other offering document has been or will be prepared in connection with the directed share issue.
Attachments:
